Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a Phase 3 clinical-stage neuropsychiatry company, announced that George Tziras, chief business officer, will present at the Jefferies Global Healthcare Conference scheduled for November 17-20, 2025, in London, United Kingdom. The company develops proprietary drug discovery platforms and delivery systems aimed at transforming mental healthcare.
This presentation holds significance as Cybin represents a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options. The company addresses the large unmet need for people suffering from mental health conditions, working to change the mental health treatment landscape through novel drugs that provide effective and durable results for patients.
Cybin's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This investigational treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to demonstrate substantial improvement over existing therapies. The company is also developing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, along with a research pipeline of investigational, 5-HT-receptor focused compounds.
The importance of Cybin's work extends beyond investor interest to broader healthcare implications. Mental health conditions represent a significant global health burden, with current treatments often providing inadequate relief for many patients. Cybin's approach to developing novel neuropsychiatry treatments could potentially offer new options for individuals who have not responded to conventional therapies. The company's operational presence across Canada, the United States, the United Kingdom, and Ireland positions it to address mental health needs across multiple healthcare systems.
Investors and healthcare professionals can access the latest news and updates relating to CYBN in the company's newsroom at https://ibn.fm/CYBN. The Jefferies conference presentation provides an opportunity for the investment community to understand Cybin's progress in developing treatments that could significantly impact mental healthcare delivery and patient outcomes worldwide.
